Is Opdivo approved for treating bladder cancer?
Opdivo is approved to treat advanced or metastatic urothelial cancer, the most common type of bladder cancer, in adults whose disease has progressed during, following, or within 12 months of first-line or adjuvant platinum-containing chemotherapy. Approximately 50% of patients with bladder cancer do not respond to their first course of chemotherapy, and only 10 to 15% of those respond to second-line chemotherapy, and Opdivo represents another treatment option for these people. Opdivo may also be used to treat adults with urothelial carcinoma that has a high risk of returning despite surgery.
- Opdivo (nivolumab) Updated 05/2022. E.R. Squibb & Sons, L.L.C. https://www.drugs.com/pro/opdivo.html
- FDA Approves Nivolumab for Bladder Cancer. March 01, 2017. National Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-nivolumab-bladder#:~:text=On%20February%202%2C%20the%20Food,the%20treatment%20of%20bladder%20cancer.
Related medical questions
- What are monoclonal antibodies?
- How long does Opdivo prolong life and what’s its success rate?
- How long does Opdivo take to work and how do you know if it's working?
- What is the difference between Opdivo and Keytruda?
- How long does Opdivo stay in your system?
- What happens when you stop taking Opdivo for melanoma?
- Is Opdivo a chemotherapy or immunotherapy drug?
- How are Opdivo and Yervoy administered?
- Is Xalkori the same as Opdivo or Keytruda?
- Pembrolizumab vs. nivolumab: how do they compare?
- What is a biologic drug?
- Opdivo Information for Consumers
- Opdivo prescribing info & package insert (for Health Professionals)
- Side Effects of Opdivo (detailed)
Related support groups
- Opdivo (16 questions, 51 members)